Last reviewed · How we verify
NCT03943212
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
NA trial testing Blood Flow Rate Reduction in ESRD in 102 participants. Completed in 24 May 2018.
24 May 2018
Quick facts
| Lead sponsor | Satellite Healthcare |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 26 September 2017 |
| Primary completion | 24 May 2018 |
| Estimated completion | 24 May 2018 |
| Sites | 18 locations across United States |
Drugs / interventions tested
- Blood Flow Rate Reduction
- Control
Conditions studied
- ESRD — all drugs for ESRD →
- Fatigue — all drugs for Fatigue →
- Hemodialysis-Induced Symptom — all drugs for Hemodialysis-Induced Symptom →
Sponsor
Satellite Healthcare — full company profile →
Who can join
Adults 18 to 89, any sex, with ESRD or Fatigue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A majority of patients with end-stage renal disease (ESRD) on in-center hemodialysis (HD) require several hours to recover from fatigue after an HD session. Evidence for practical interventions to improve this recovery time from conventional in-center HD is lacking. This study investigates the effects of reducing HD blood flow rates on patients' self-reported post-dialysis fatigue.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03943212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ESRD
Currently open trials in the same condition.
- NCT06913647 — Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis · Phase 2 · recruiting
- NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
- NCT05339139 — SAfety of Regional Citrate Anticoagulation (SARCA Study) · Phase 3 · recruiting
- NCT05434325 — TESTING -ON Post-Trial ObservatioNal Cohort Study · recruiting
- NCT05309785 — Safety and Efficacy of Canagliflozin in Advanced CKD · Phase 4 · active not recruiting
Other Satellite Healthcare trials
Trials by the same sponsor.
- NCT05400720 — Peer Support In Dialysis · NA · completed
- NCT05011136 — Physician Reimbursement Home Patients · completed
- NCT05022225 — Psychosocial Reasons for Transfer to In Center Hemodialysis in Home Dialysis Patients- A Focus Group Study · completed
- NCT04988568 — Experience of Patients Starting Hemodialysis · completed
- NCT04806126 — Evaluation of a Virtual Home Dialysis Mentoring Program (Home) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03943212 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Satellite Healthcare
- Last refreshed: 9 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing